Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors

Targeting Survivin with YM155 (Sepantronium Bromide): A novel therapeutic strategy for paediatric acute myeloid leukaemia

(2015) Amanda M. Smith et al.   LEUKEMIA RESEARCH

Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus

(2015) J. S. Carew et al.   MOLECULAR CANCER THERAPEUTICS

Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: The Children's Hospital Los Angeles experience

(2014) Jesse L Berry et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant

(2014) Hiroki Kawano et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

(2013) R. J. Kelly et al.   ANNALS OF ONCOLOGY

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

(2013) J. Chen et al.   BLOOD

Treat cancers by targeting survivin: Just a dream or future reality?

(2013) Mohane Selvaraj Coumar et al.   CANCER TREATMENT REVIEWS

Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma

(2013) Emiliano Buitrago et al.   EXPERIMENTAL EYE RESEARCH

Hypoxic tumor microenvironment in advanced retinoblastoma

(2013) Job Sudhakar et al.   PEDIATRIC BLOOD & CANCER

Aminoimidazole Carboxamide Ribonucleotide (AICAR) Inhibits the Growth of Retinoblastoma In Vivo by Decreasing Angiogenesis and Inducing Apoptosis

(2013) Sofia Theodoropoulou et al.   PLoS One

Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma

(2013) Jasmine H. Francis et al.   PLoS One

Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats

(2012) Tsuyoshi Minematsu et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response

(2012) Trevor G. Glaros et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Retinoblastoma frontiers with intravenous, intra-arterial, periocular and intravitreal chemotherapy

(2012) C L Shields et al.   EYE

Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells

(2011) Qinwen Wang et al.   CANCER LETTERS

Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models

(2011) Kentaro Yamanaka et al.   CLINICAL CANCER RESEARCH

Induction of Apoptosis by Survivin Silencing through siRNA Delivery in a Human Breast Cancer Cell Line

(2011) Hamidreza Montazeri Aliabadi et al.   MOLECULAR PHARMACEUTICS

Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma

(2011) Kiran Turaka et al.   PEDIATRIC BLOOD & CANCER

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant and platinum-based drugs

(2010) T Iwasa et al.   BRITISH JOURNAL OF CANCER

Survivin as a global  target of intrinsic tumor suppression networks

(2010) Minakshi Guha et al.   CELL CYCLE

Superselective Ophthalmic Artery Chemotherapy as Primary Treatment for Retinoblastoma (Chemosurgery)

(2010) David H. Abramson et al.   OPHTHALMOLOGY

FOCAL PERIOCULAR CARBOPLATIN CHEMOTHERAPY AVOIDS SYSTEMIC CHEMOTHERAPY FOR UNILATERAL, PROGRESSIVE RETINOBLASTOMA

(2010) THEODORE LENG et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity

(2009) J. Shen et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Frontiers in the Management of Retinoblastoma

(2009) Phoebe Lin et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Survivin: A new target for anti-cancer therapy

(2009) Bríd M. Ryan et al.   CANCER TREATMENT REVIEWS

Detection of survivin protein in aqueous humor and serum of retinoblastoma patients and its clinical significance

(2009) Hanan H. Shehata et al.   CLINICAL BIOCHEMISTRY

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

(2009) T. Satoh et al.   CLINICAL CANCER RESEARCH

Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

(2009) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Cause-Specific Mortality in Long-Term Survivors of Retinoblastoma

(2009) C.-L. Yu et al.   JNCI-Journal of the National Cancer Institute

Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression

(2009) S. Konduri et al.   MOLECULAR CANCER THERAPEUTICS

Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma

(2009) Mathilde Jehanne et al.   PEDIATRIC BLOOD & CANCER

Incidence of retinoblastoma in the USA: 1975-2004

(2008) E Broaddus et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines

(2008) T. Iwasa et al.   CLINICAL CANCER RESEARCH

Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma

(2008) C. L. Dalgard et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

(2008) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of Second Malignancies in Survivors of Retinoblastoma: More Than 40 Years of Follow-up

(2008) Tamara Marees et al.   JNCI-Journal of the National Cancer Institute